Neurox - instructions for use, dose, side effects, contraindications

Ethyl methylhydroxypyridine succinate (EMGPS) is an inhibitor of free radical processes, a membrane protector possessing antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. Refers to the class of 3-oxypyridines. The mechanism of action is due to antioxidant and membrane-protective properties. Suppresses lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid-protein, improves the structure and function of the cell membrane.Modulates the activity of membrane-bound enzymes, receptor complexes, which facilitates their binding to ligands, the preservation of the structurally functional organization of biomembranes, the transport of neurotransmitters, and the improvement of synaptic transmission. Increases the concentration in the brain of dopamine. Enhances compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in adenosine triphosphate and creatine phosphate, activates the energy-producing function of mitochondria. Increases the resistance of the body to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs). It improves the metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. Has hypolipidemic action, reduces the content of total cholesterol and low density lipoproteins.Normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and / or improves electrical activity and myocardial contractility, and also increases coronary blood flow in the ischemic zone, increases the antianginal activity of nitro drugs, reduces the effects of reperfusion syndrome in acute coronary insufficiency.

The stress-protective action is manifested in the normalization of post-stress behavior, somatovegetative disorders, the restoration of sleep-wake cycles, disrupted learning and memory processes, and the reduction of dystrophic changes in various structures of the brain.

Ethyl methyl mercaptopyridine succinate has a pronounced antitoxic effect on withdrawal symptoms, eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, corrects behavioral and cognitive impairments. Under the influence of ethylmethylhydroxypyridine succinate, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which allows to reduce their doses and reduce side effects.

Pharmacokinetics:

When administered intramuscularly, the drug is determined in the blood plasma for 4 hours after administration. The time to reach the maximum concentration for intramuscular injection is 0.3-0.58 hours. The maximum concentration for intramuscular injection at a dose of 400-500 mg is 2.5-4 μg / ml. Ethyl methylhydroxypyridine succinate quickly passes from the bloodstream into organs and tissues and is rapidly excreted from the body. The average retention time of the drug in the body with intramuscular injection is 0.7-1.3 hours. It is metabolized in the liver by glucuronation. It is quickly excreted in the urine mainly in the form of metabolites (50% in 12 hours) and in an insignificant amount - unchanged (0.3% per 12 hours). The most intensive output is for the first 4 hours after taking the drug. The indices of excretion in the urine of unchanged drug and metabolites have a significant individual variability.

Indications:

- Acute disorders of cerebral circulation (as part of complex therapy);

- craniocerebral trauma, consequences of craniocerebral injuries;

- encephalopathy;

- syndrome of vegetative (neurocirculatory) dystonia;

- light cognitive disorders of atherosclerotic origin;

- anxiety disorders in neurotic and neurosis-like states;

- acute myocardial infarction (from the first day) as part of complex therapy;

- primary open-angle glaucoma of various stages, as part of complex therapy;

- relief of withdrawal syndrome with alcoholism with prevalence of neurosis-like and vegetative-vascular disorders;

- acute intoxication with antipsychotic drugs.

Contraindications:

- Pexcessive individual sensitivity to the drug or its components;

- acute renal insufficiency;

- acute liver failure;

- pregnancy;

- breast-feeding;

- childhood.

Carefully:

Allergic diseases and reactions in the anamnesis, including hypersensitivity to sulfites.

Dosing and Administration:

Intramuscularly (in / m) or intravenously (intravenously) (jet or drip). With the infusion method of administration, the drug should be diluted in a 0.9% solution of sodium chloride. Jet Neurox® is injected slowly for 5-7 minutes, drip - at a speed of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

In acute disorders of cerebral circulation Neurox® is used in complex therapy in the first 10-14 days - intravenous drip 200-500 mg 2-4 times a day, then 200-250 mg intravenously 2-3 times a day for 2 weeks.

In case of craniocerebral trauma and consequences of craniocerebral injuries Neurox® is used for 10-15 days IV in a drip of 200-500 mg 2-4 times a day.

With discirculatory encephalopathy in the phase of decompensation Neurox® should be administered intravenously or in droplet at a dose of 200-500 mg 1-2 times a day for 14 days. Then - in / m at 100-250 mg / day for the next 2 weeks.

For the course of prophylaxis of dyscirculatory encephalopathy Neurox® is given in / m at a dose of 200-250 mg twice a day for 10-14 days.

With neurocirculatory dystonia, neurotic and neurosis-like states the drug is administered in / m at 50-400 mg per day for 14 days.

With mild cognitive impairment in elderly patients and with anxiety disorders the drug is used in / m at a dose of 100-300 mg per day for 14-30 days.

With acute myocardial infarction as part of complex therapy Neurox® is administered intravenously or intravenously for 14 days against the background of traditional therapy of myocardial infarction (including nitrates, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, and symptomatic means on indications).

In the first 5 days, Neurox® is administered intravenously, and for the next 9 days the drug can be administered intramuscularly. Intravenous administration of the drug is carried out by dropwise infusion (slowly) for 30-90 minutes (in 100-150 ml of a 0.9% solution of sodium chloride or 5% solution of dextrose (glucose)), if necessary, a slow jet intravenous injection, duration of not less than 5 minutes. Administration of the drug (iv or IM) is carried out 3 times a day, every 8 hours, the daily dose is 6-9 mg / kg body weight, single dose - 2-3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

With open-angle glaucoma various stages in the complex therapy Neurox® is administered in / m at 100-300 mg / day, 1 -3 times a day for 14 days.

With abstinence alcohol syndrome Neurox® is administered intravenously or intravenously at a dose of 200-500 mg 2-3 times a day for 5-7 days.

In acute intoxication with antipsychotic drugs the drug is administered IV in a dose of 200-500 mg / day for 7-14 days.

Side effects:

When parenteral administration (especially intravenous jet): dryness, "metallic" taste in the mouth,sensations of "spilling heat" throughout the body, sore throat and discomfort in the chest, a sense of lack of air (usually associated with an excessively high rate of administration and are of a short duration).

With prolonged use - nausea, flatulence, sleep disturbances (drowsiness or falling asleep).

Allergic reactions.

Overdose:

Symptoms: sleep disorders (insomnia, in some cases - drowsiness); at intravenous introduction - insignificant and short-term (up to 1,5-2 ch) increase of arterial pressure.

Treatment: as a rule, is not required - the symptoms disappear on their own, during the day. In severe cases with insomnia - nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg. With excessive increase in blood pressure - hypotensive drugs under the control of blood pressure.

Interaction:

Enhances the action of benzodiazepine anxiolytics, antiepileptic (carbamazepine), antiparkinsonian (levodopa) of medicines, nitrates.

Reduces the toxic effects of ethanol.

Effect on the ability to drive transp. cf. and fur:

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

Solution for intravenous and intramuscular injection, 50 mg / ml.

Packaging:

2 ml per ampoule of light-protective glass with a color fracture ring or with a colored dot and a notch. One, two or three color rings and / or a two-dimensional bar code, and / or alphanumeric coding or without additional color rings, a two-dimensional bar code, and alphanumeric coding are additionally applied to the ampoules. 5 ampoules per contour cell pack.

By 1, 2, 4 or 10 contour mesh packages together with instructions for use in a pack of cardboard.

5 ml per ampoule of light-protective glass with a color fracture ring or with a colored dot and a notch. One, two or three color rings and / or a two-dimensional bar code, and / or alphanumeric coding or without additional color rings, a two-dimensional bar code, and alphanumeric coding are additionally applied to the ampoules. 5 ampoules per contour cell pack.

For 1, 2, 4 contour mesh packages together with instructions for use in a pack of cardboard.

For 10 ml or 20 ml in ampoules of light-protective glass with a color fracture ring or with a colored dot and a notch. One, two or three color rings and / or a two-dimensional bar code, and / or alphanumeric coding or without additional color rings, a two-dimensional bar code, and alphanumeric coding are additionally applied to the ampoules. 1 ampoule per circuit pack. On 1 contour acheikova packing together with the instruction on application in a pack from a cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-007439/09

Date of registration:24.09.2009

The owner of the registration certificate:FarmSirma Soteks, ZAO FarmSirma Soteks, ZAO Russia

Manufacturer: & nbsp

FarmSirma Soteks, ZAO Russia

Representation: & nbspPharm Company Sotex CJSC Pharm Company Sotex CJSC Russia

Information update date: & nbsp10.10.2015

Illustrated instructions

Instructions

Neurox® (Neurox®)